Patricia A. Nunes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patricia A. Nunes has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Isabel Sá-Correia
BB—Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1, 1049-001 Lisbon, Portugal
2 shared publications Laurence M. Elandalloussi
Molecular Biology and Biotechnology, CCMar, University of Algarve-Campus de Gambelas, 8005-139 Faro, Portugal
2 shared publications- Maria Leonor Cancela
Centre of Marine Sciences, University of Algarve, 8005-139 Faro, Portugal
2 shared publications Ricardo Afonso
Molecular Biology and Biotechnology, CCMar, University of Algarve—Campus de Gambelas, 8005-139 Faro, Portugal
2 shared publications- Sandra Tenreiro
NOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, Lisboa, Portugal
2 shared publications - Cristina Anjinho Viegas
Instituto Superior Técnico
1 shared publication
Latest Publications
- 2 December 2003
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 18 (2) , 89-96
Development of a PCR-ELISA assay for diagnosis of Perkinsus marinus and Perkinsus atlanticus infections in bivalve molluscs
- 2 December 2003
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 18 (2) , 89-96
Development of a PCR-ELISA assay for diagnosis of Perkinsus marinus and Perkinsus atlanticus infections in bivalve molluscs
- 19 June 2003
- Published by Elsevier in Biomolecular Engineering
- Vol. 20 (4-6) , 349-354
Effect of desferrioxamine and 2,2′-bipyridyl on the proliferation of Perkinsus atlanticus
- 19 June 2003
- Published by Elsevier in Biomolecular Engineering
- Vol. 20 (4-6) , 349-354
Effect of desferrioxamine and 2,2′-bipyridyl on the proliferation of Perkinsus atlanticus
- 1 April 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 292 (3) , 741-748
AQR1 Gene (ORF YNL065w) Encodes a Plasma Membrane Transporter of the Major Facilitator Superfamily That Confers Resistance to Short-Chain Monocarboxylic Acids and Quinidine in Saccharomyces cerevisiae
- 1 April 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 292 (3) , 741-748
AQR1 Gene (ORF YNL065w) Encodes a Plasma Membrane Transporter of the Major Facilitator Superfamily That Confers Resistance to Short-Chain Monocarboxylic Acids and Quinidine in Saccharomyces cerevisiae
- Open Access
- 1 May 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (5) , 1528-1534
Resistance and Adaptation to Quinidine inSaccharomyces cerevisiae: Role ofQDR1(YIL120w), Encoding a Plasma Membrane Transporter of the Major Facilitator Superfamily Required for Multidrug Resistance
As predicted based on structural considerations, we show results indicating that the member of the major facilitator superfamily encoded bySaccharomyces cerevisiaeopen reading frameYIL120wis a multidrug resistance determinant. Yil120wp was implicated in yeast resistance to ketoconazole and quinidine, but not to the stereoisomer quinine; the gene was thus namedQDR1. Qdr1p was proved to alleviate the deleterious effects of quinidine, revealed by the loss of cell viability following sudden exposure of the unadapted yeast population to the drug, and to allow the earlier eventual resumption of exponential growth under quinidine stress. However,QDR1gene expression had no detectable effect on the susceptibility of yeast cells previously adapted to quinidine. Fluorescence microscopy observation of the distribution of the Qdr1-green fluorescent protein fusion protein in living yeast cells indicated that Qdr1p is a plasma membrane protein. We also show experimental evidence indicating that yeast adaptation to growth with quinidine involves the induction of active expulsion of the drug from preloaded cells, despite the fact that this antiarrhythmic and antimalarial quinoline ring-containing drug is not present in the yeast natural environment. However, we were not able to prove that Qdr1p is directly implicated in this export. Results clearly suggest that there are other unidentified quinidine resistance mechanisms that can be used in the absence ofQDR1.
- 1 May 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (5) , 1528-1534
Open AccessResistance and Adaptation to Quinidine inSaccharomyces cerevisiae: Role ofQDR1(YIL120w), Encoding a Plasma Membrane Transporter of the Major Facilitator Superfamily Required for Multidrug Resistance
As predicted based on structural considerations, we show results indicating that the member of the major facilitator superfamily encoded bySaccharomyces cerevisiaeopen reading frameYIL120wis a multidrug resistance determinant. Yil120wp was implicated in yeast resistance to ketoconazole and quinidine, but not to the stereoisomer quinine; the gene was thus namedQDR1. Qdr1p was proved to alleviate the deleterious effects of quinidine, revealed by the loss of cell viability following sudden exposure of the unadapted yeast population to the drug, and to allow the earlier eventual resumption of exponential growth under quinidine stress. However,QDR1gene expression had no detectable effect on the susceptibility of yeast cells previously adapted to quinidine. Fluorescence microscopy observation of the distribution of the Qdr1-green fluorescent protein fusion protein in living yeast cells indicated that Qdr1p is a plasma membrane protein. We also show experimental evidence indicating that yeast adaptation to growth with quinidine involves the induction of active expulsion of the drug from preloaded cells, despite the fact that this antiarrhythmic and antimalarial quinoline ring-containing drug is not present in the yeast natural environment. However, we were not able to prove that Qdr1p is directly implicated in this export. Results clearly suggest that there are other unidentified quinidine resistance mechanisms that can be used in the absence ofQDR1.